Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications

Published on Apr 9, 2018in Pharmaceuticals4.286
· DOI :10.3390/PH11020032
Nirnoy Dan6
Estimated H-index: 6
(UTHSC: University of Tennessee Health Science Center),
Saini Setua7
Estimated H-index: 7
(UTHSC: University of Tennessee Health Science Center)
+ 4 AuthorsSubhash C. Chauhan49
Estimated H-index: 49
(UTHSC: University of Tennessee Health Science Center)
Sources
Abstract
Chemotherapy is one of the major therapeutic options for cancer treatment. Chemotherapy is often associated with a low therapeutic window due to its poor specificity towards tumor cells/tissues. Antibody-drug conjugate (ADC) technology may provide a potentially new therapeutic solution for cancer treatment. ADC technology uses an antibody-mediated delivery of cytotoxic drugs to the tumors in a targeted manner, while sparing normal cells. Such a targeted approach can improve the tumor-to-normal tissue selectivity and specificity in chemotherapy. Considering its importance in cancer treatment, we aim to review recent efforts for the design and development of ADCs. ADCs are mainly composed of an antibody, a cytotoxic payload, and a linker, which can offer selectivity against tumors, anti-cancer activity, and stability in systemic circulation. Therefore, we have reviewed recent updates and principal considerations behind ADC designs, which are not only based on the identification of target antigen, cytotoxic drug, and linker, but also on the drug-linker chemistry and conjugation site at the antibody. Our review focuses on site-specific conjugation methods for producing homogenous ADCs with constant drug-antibody ratio (DAR) in order to tackle several drawbacks that exists in conventional conjugation methods.
Figures & Tables
Download
📖 Papers frequently viewed together
180 Citations
726 Citations
193 Citations
References123
Newest
#1Kyoji Tsuchikama (University of Texas Health Science Center at Houston)H-Index: 19
#2Zhiqiang An (University of Texas Health Science Center at Houston)H-Index: 55
The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This new antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamic...
180 CitationsSource
#1Patrick J. KennedyH-Index: 9
#2Carla Oliveira (University of Porto)H-Index: 62
Last. Bruno Sarmento (University of Porto)H-Index: 67
view all 4 authors...
Abstract Monoclonal antibodies (mAbs) are well established in the clinic due to their specificity and affinity to a diverse array of biochemical targets. More recently, mAbs are being exploited as targeting agents in modern drug delivery systems, aiming to bypass normal host tissue and to accumulate a therapeutic agent to a specific tissue or cell for enhanced pharmacology. At sizes ranging from ~ 10–100 nm, antibody-based bioconjugates have opened up a whole new realm of clinical possibilities ...
36 CitationsSource
#1Kathleen N. Moore (University of Oklahoma Health Sciences Center)H-Index: 45
#2Hossein Borghaei (Fox Chase Cancer Center)H-Index: 48
Last. Michael J. BirrerH-Index: 109
view all 13 authors...
BACKGROUND Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate that selectively targets folate receptor α (FRα). In this phase 1 dose-escalation study, the authors investigated IMGN853 in patients with FRα-positive solid tumors. METHODS Patients received IMGN853 on day 1 of a 21-day cycle (once every 3 weeks dosing), with cycles repeated until patients experienced dose-limiting toxicity or progression. Dose escalation commenced in single-patient cohorts for the first 4 planned dose...
31 CitationsSource
#1Kathleen N. Moore (University of Oklahoma Health Sciences Center)H-Index: 45
#2Lainie P. Martin (Fox Chase Cancer Center)H-Index: 28
Last. Michael J. Birrer (Sarah Cannon Research Institute)H-Index: 109
view all 9 authors...
PurposeThis phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody–drug conjugate consisting of a humanized anti–folate receptor alpha (FRα) monoclonal antibody linked to the tubulin-disrupting maytansinoid DM4, in a population of patients with FRα-positive and platinum-resistant ovarian cancer.Patients and MethodsPatients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer received IMGN85...
71 CitationsSource
#1Julia Mantaj ('KCL': King's College London)H-Index: 5
#2Paul J. M. Jackson ('KCL': King's College London)H-Index: 10
Last. David E. Thurston ('KCL': King's College London)H-Index: 54
view all 4 authors...
The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of sequence-selective DNA minor-groove binding agents that form a covalent aminal bond between their C11-position and the C2-NH2 groups of guanine bases. The first example of a PBD monomer, the natural product anthramycin, was discovered in the 1960s, and the best known PBD dimer, SJG-136 (also known as SG2000, NSC 694501 or BN2629), was synthesized in the 1990s and has recently completed Phase II clinical trials in patients with leukaem...
112 CitationsSource
#1Jose F. Ponte (ImmunoGen, Inc.)H-Index: 10
#2Olga Ab (ImmunoGen, Inc.)H-Index: 10
Last. Rodrigo Ruiz-Soto (ImmunoGen, Inc.)H-Index: 7
view all 10 authors...
Abstract Elevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian cancer (EOC), thus establishing this receptor as a candidate target for the development of novel therapeutics to treat this disease. Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that targets FRα for tumor-directed delivery of the maytansinoid DM4, a potent agent that induces mitotic arrest by suppressing microtubule dynamics. Here, combinations of IMGN853 with approved ther...
29 CitationsSource
#1Frank Loganzo (Pfizer)H-Index: 17
#2Matthew Sung (Pfizer)H-Index: 9
Last. Hans-Peter Gerber (Pfizer)H-Index: 18
view all 3 authors...
Drug resistance limits the effectiveness of cancer therapies. Despite attempts to develop curative anticancer treatments, tumors evolve evasive mechanisms limiting durable responses. Hence, diverse therapies are used to attack cancer, including cytotoxic and targeted agents. Antibody–drug conjugates (ADC) are biotherapeutics designed to deliver potent cytotoxins to cancer cells via tumor-specific antigens. Little is known about the clinical manifestations of drug resistance to this class of ther...
56 CitationsSource
#1Joyce F. Liu (Harvard University)H-Index: 40
#2Kathleen N. Moore (University of Oklahoma Health Sciences Center)H-Index: 45
Last. H. A. Burris (Sarah Cannon Research Institute)H-Index: 42
view all 21 authors...
Background MUC16 is a tumor-specific antigen overexpressed in ovarian (OC) and pancreatic (PC) cancers. The antibody–drug conjugate (ADC), DMUC5754A, contains the humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting agent, monomethyl auristatin E (MMAE). Patients and methods This phase I study evaluated safety, pharmacokinetics (PK), and pharmacodynamics of DMUC5754A given every 3 weeks (Q3W, 0.3–3.2 mg/kg) or weekly (Q1W, 0.8–1.6 mg/kg) to patients with advanced rec...
38 CitationsSource
#1Pavel Strop (Pfizer)H-Index: 22
#2Thomas-Toan Tran (Pfizer)H-Index: 10
Last. Shu-Hui Liu (Pfizer)H-Index: 11
view all 17 authors...
Trop-2, also known as TACSTD2, EGP-1, GA733-1 and M1S1, is frequently expressed on a variety of human carcinomas and its expression is often associated with poor prognosis of the diseases. However, it is also present on the epithelium of several normal tissues. A comprehensively designed Trop-2-targeting ADC, balancing both efficacy and toxicity, is therefore necessary to achieve clinical utility. To this end, we developed a cleavable Trop-2-ADC (RN927C) using a site-specific transglutaminase-me...
36 CitationsSource
#1Andre Goy (Hackensack University Medical Center)H-Index: 51
#2Andres Forero (UAB: University of Alabama at Birmingham)H-Index: 42
Last. Michinori OguraH-Index: 53
view all 10 authors...
This phase 2 study evaluated the efficacy and safety of inotuzumab ozogamicin (InO) in patients with indolent B-cell non-Hodgkin lymphoma (NHL) refractory to rituximab alone, rituximab plus chemotherapy or anti-CD20 radioimmunotherapy. Patients received InO 1·8 mg/m(2) intravenously on a 28-d cycle for a planned 4-8 cycles. The initial InO dose and schedule could be adjusted for tolerability and patients were allowed to receive 2 additional cycles (up to 8 total) after achieving a complete respo...
26 CitationsSource
Cited By82
Newest
#1Fabio Lievano (AbbVie)H-Index: 12
#2Linda Scarazzini (AbbVie)H-Index: 4
Last. Cheryl L. Renz (AbbVie)
view all 5 authors...
Antibody-drug conjugates (ADCs) are new treatment options for certain cancers, especially those in advanced states with limited treatment options. Their unique design provides targeted therapy with toxins that otherwise would not be available, but they manifest toxicities that require risk minimization interventions to optimize their tolerability. We summarize selected toxicities for ADCs that have been approved through the end of 2020 and three investigational ADCs, which include both payload a...
Source
#1Iljae MinH-Index: 1
#2Takanori UzawaH-Index: 12
Last. Yoshihiro ItoH-Index: 61
view all 4 authors...
Using polymerase chain reaction (PCR)-mediated recombination, single ribonucleic acid (RNA) chains containing bifunctional RNA sequences involving substrate binding and phosphorescent signaling were prepared. For substrate binding and phosphorescent labeling, thrombin- or lysozyme-binding and ruthenium complex-binding RNA aptamer sequences were used. It was demonstrated that the structural properties of the conjugated RNAs showed similar characteristics to the original aptamers using circular di...
Source
#1Wangyujing Han (ECNU: East China Normal University)H-Index: 1
#2Yu Jie (ECNU: East China Normal University)
Last. Shunying Liu (ECNU: East China Normal University)H-Index: 22
view all 10 authors...
A Pd-catalyzed multicomponent reaction was developed by trapping oxomium ylide with nitrosobenzene via Pd-promoted umpolung chemistry. The Pd catalyst plays two important roles: diazo compound decomposed catalyst and Lewis acid for the activation of nitrosobenzene. This strategy provides some insight into a new way for discovery of multicomponent methodology to construct complex molecules. The developed method also provides rapid access to a series of O-(2-oxy) hydroxylamine derivatives, which e...
Source
Antibodies against inhibitory immune checkpoint molecules (ICPMs), referred to as immune checkpoint inhibitors (ICIs), have gained a prominent place in cancer therapy. Several ICIs in clinical use have been engineered to be devoid of effector functions because of the fear that ICIs with preserved effector functions could deplete immune cells, thereby curtailing antitumor immune responses. ICPM ligands (ICPMLs), however, are often overexpressed on a sizeable fraction of tumor cells of many tumor ...
Source
#1Haozhong DingH-Index: 3
#2Tianqi XuH-Index: 2
Last. Anzhelika VorobyevaH-Index: 10
view all 8 authors...
Affibody molecules hold great promise as carriers of cytotoxic drugs for cancer therapy due to their typically high affinity, easy production, and inherent control of the drug molecules' loading and spatial arrangement. Here, the impact of increasing the drug load from one to three on the properties of an affibody drug conjugate targeting the human epidermal growth factor receptor 2 (HER2) was investigated. The affibody carrier was recombinantly expressed as a fusion to an albumin-binding domain...
Source
#1Jacopo MillulH-Index: 3
#2Christiane Krudewig (UZH: University of Zurich)H-Index: 2
Last. Samuele CazzamalliH-Index: 9
view all 8 authors...
Small molecule-drug conjugates (SMDCs) represent an alternative to conventional anti-tumor chemotherapeutic agents, with the potential to improve the therapeutic window of cytotoxic payloads through active delivery at the site of the disease. In this article we describe novel combination therapies consisting of anti-Carbonic Anhydrase IX SMDCs combined with different immunomodulatory products. The therapeutic effect of the SMDCs was potentiated by combination with PD-1 blockade and with tumor-ho...
1 CitationsSource
#1Henrik Franzyk (UCPH: University of Copenhagen)H-Index: 28
#2Søren Christensen (UCPH: University of Copenhagen)H-Index: 97
Last. Søren Brøgger Christensen (UCPH: University of Copenhagen)
view all 2 authors...
Many cancer diseases, e.g., prostate cancer and lung cancer, develop very slowly. Common chemotherapeutics like vincristine, vinblastine and taxol target cancer cells in their proliferating states. In slowly developing cancer diseases only a minor part of the malignant cells will be in a proliferative state, and consequently these drugs will exert a concomitant damage on rapidly proliferating benign tissue as well. A number of toxins possess an ability to kill cells in all states independently o...
1 CitationsSource
#1Tamara G. Dacoba (University of Santiago de Compostela)H-Index: 5
#2Shubaash Anthiya (University of Santiago de Compostela)H-Index: 1
Last. María J. Alonso (University of Santiago de Compostela)H-Index: 102
view all 9 authors...
1 CitationsSource
#1Marie Rütter (BGU: Ben-Gurion University of the Negev)H-Index: 2
#2Nenad Milošević (BGU: Ben-Gurion University of the Negev)H-Index: 1
Last. Ayelet David (BGU: Ben-Gurion University of the Negev)H-Index: 17
view all 3 authors...
The vast majority of nanomedicines (NM) investigated today consists of a macromolecular carrier and a drug payload (conjugated or encapsulated), with a purpose of preferential delivery of the drug to the desired site of action, either through passive accumulation, or by active targeting via ligand-receptor interaction. Several drug delivery systems (DDS) have already been approved for clinical use. However, recent reports are corroborating the notion that NM do not necessarily need to include a ...
Source
#1Homa Seyedmirzaei (Education and Research Network)
#2Mahsa Keshavarz-Fathi (Education and Research Network)H-Index: 8
Last. Nima Rezaei (Education and Research Network)H-Index: 80
view all 5 authors...
ObjectiveBreast cancer is responsible for most of the cancer-induced deaths in women around the world. The current review will discuss different approaches of targeting HER2, an epidermal growth fa...
Source